Development and optimization of vildagliptin solid lipid nanoparticles loaded ocuserts for controlled ocular delivery: A promising approach towards treating diabetic retinopathy

• Main Authors: Abd El hakim Ramadan (Author), Mahmoud M.A. Elsayed (Author), Amani Elsayed (Author), Marwa A. Fouad (Author), Mohamed S. Mohamed (Author), Sangmin Lee (Author), Reda A. Mahmoud (Author), Shereen A. Sabry (Author), Mohammed M. Ghoneim (Author), Ahmed H.E. Hassan (Author), Reham A. Abd Elkarim (Author), Amany Belal (Author), Ahmed A. El-Shenawy (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic effect, VLD minimizes ocular inflammation and improve...